FZD, Human (Vantictumab biosimilar) Antibody from KMD BIOSCIENCE CO. LTD.

Search, find, compare suppliers for anti-FZD, Human (Vantictumab biosimilar) antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityFZD, Human (Vantictumab biosimilar)
CloneVantictumab
Host SpeciesRecombinant
Reactive Specieshuman
IsotypeIgG2 lambda
Formatpurified
Size1mg, 5mg
Concentration1mg/ml
ApplicationsInhib, FCM
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionAnti-Human FZD Recombinant Antibody. Vantictumab /vaen t kt maeb/ is a human IgG2 monoclonal antibody designed for the treatment of cancer. This drug was developed by OncoMed Pharmaceuticals Inc. in partnership with Bayer. OncoMed was awarded a patent in 2016, which is set to expire in 2029.[3] In April 2017, Bayer terminated its option to license vantictumab.
Immunogenn/a
Other NamesAnti-FZD Recombinant Antibody, Research Grade Vantictumab, Anti-Human FZD Recombinant Antibody, OMP-18R5, Antibody Drug Analogues, Monoclonal Antibody, YR1315, Research Grade Biosimilars, Biosimilar Antibody
Gene, Accession #CAS: 1345009-45-1
Catalog #YR1315
Priceplease inquire
Order / More InfoFZD, Human (Vantictumab biosimilar) Antibody from KMD BIOSCIENCE CO. LTD.
Product Specific Referencesn/a
KMD BIOSCIENCE CO. LTD.
KMD BIOSCIENCE CO. LTD.
KMD BIOSCIENCE CO. LTD.
FL-4, Building A5
International Enterprise Community
Tianjin CHINA
P: 400-621-6806

info@kmdbioscience.com
Sales: sales@kmdbiosci.com

https://www.kmdbioscience.com

Profile of KMD BIOSCIENCE CO. LTD.

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.